Market Overview:
The global nuclear medicine market is expected to reach USD XX million by 2030, at a CAGR of XX% during the forecast period 2018-2030. The growth in this market can be attributed to factors such as rising incidence of cancer, technological advancements in nuclear medicine and increasing demand for SPECT and PET scans. However, the high cost of equipment and stringent regulatory norms are restraining the growth of this market. Based on type, the global nuclear medicine market is segmented into Tc-99m, I-123/131m, In-111m, Xe-133m,, Th-201m,, Ga-67 citrate and other isotopes. Tc99 dominates the global nuclear medicine market owing to its widespread use in cardiac stress tests and bone scans. Iodine (I123/131) is also used extensively for thyroid imaging and other diagnostic applications. In terms of application, the global nuclear medicine market is divided into diagnostic applications and therapeutic applications. The diagnostic segment dominates this market due to rising demand for SPECT (single photon emission computed tomography)and PET (positron emission tomography) scans across all regions studied in this research study .
Product Definition:
Nuclear Medicine is a branch of medical imaging that uses small amounts of radioactive material to diagnose and treat disease. It is used to diagnose and treat problems such as cancer, heart disease, and thyroid problems.
Tc-99:
Tc-99 is a radioactive tracer used in medical imaging. It is mainly employed to locate and track the flow of blood within the human body. However, it can also be used for other applications such as localization of tumors or inflammation. Tc-99m is an artificial radiotracer that closely resembles tetrachloroethylene (TCE) 99; hence it was named after its chemical structure.
I-123/131:
I-123/131 is a radioisotope used in nuclear medicine for the diagnosis of cancer and other diseases. It is an organic compound which consists of carbon, hydrogen, nitrogen & oxygen and has a molecular weight of 131.8 (C+N+O) & 123.0 (HCO3). I-123/131 was first produced by Fermi National Laboratory in America as an alternative to I-90 for medical use back in 1980s.
Application Insights:
The diagnostic application segment dominated the global nuclear medicine market in 2017. The growth of this segment can be attributed to the growing adoption of these techniques for the diagnosis of cancer and other diseases. For instance, In-111 is widely used for imaging purposes in oncology as it provides high bone/tissue contrast and short half-life which makes it suitable for PET/CT imaging.
Tc-99m sulfur colloid is most commonly used for cardiology applications due to its ability to detect even very small amounts of tissue damage caused by myocardial infarction or angina pectoris without causing any harm to heart muscles. However, Tc-99m suffers from disadvantages such as low availability (stockage) and short half life which restrict its use in cardiology applications compared with that required in oncology or neurology applications.
Regional Analysis:
North America dominated the global nuclear medicine market in 2016 with a revenue share of over 35%. The growth can be attributed to the presence of major players, high investment in R&D, and favorable reimbursement scenario. In addition, increasing applications for nuclear scans is further expected to drive regional growth. For instance, according to American Cancer Society (ACS), Inc., around 1.6 million new cases were estimated to be diagnosed by 2020 in U.S.
Asia Pacific is anticipated witness lucrative growth over the forecast period owing its large patient pool and improving healthcare infrastructure coupled with economic development & growing medical tourism industry especially after China’s 13th Five Year Plan was implemented in 2011 aimed at achieving sustainable economic development through innovation-driven transformation (IDT).
Growth Factors:
- Increasing incidence of cancer and other diseases that can be treated with nuclear medicine
- Growing demand for PET scans to diagnose and stage cancer
- Advances in nuclear medicine technology that make it easier to use and more accurate
- Increased focus on cost-effective healthcare delivery
- Rising awareness of the benefits of nuclear medicine
Scope Of The Report
Report Attributes
Report Details
Report Title
Nuclear Medicine Market Research Report
By Type
Tc-99, I-123/131, In-111, Xe-133, Th-201, Ga-67, Other, Nuclear Medicin
By Application
Diagnostic, Therapeutic
By Companies
GE Healthcare, Bracco Imaging, Mallinckrodt, Lantheus Medical Imaging, Bayer, Triad Isotopes, Nordion, Jubilant Pharma, Eli Lilly, SIEMENS, China Isotope & Radiation, Dongcheng, Nuclear Medicin
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Nuclear Medicine Market Report Segments:
The global Nuclear Medicine market is segmented on the basis of:
Types
Tc-99, I-123/131, In-111, Xe-133, Th-201, Ga-67, Other, Nuclear Medicin
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Diagnostic, Therapeutic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GE Healthcare
- Bracco Imaging
- Mallinckrodt
- Lantheus Medical Imaging
- Bayer
- Triad Isotopes
- Nordion
- Jubilant Pharma
- Eli Lilly
- SIEMENS
- China Isotope & Radiation
- Dongcheng
- Nuclear Medicin
Highlights of The Nuclear Medicine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tc-99
- I-123/131
- In-111
- Xe-133
- Th-201
- Ga-67
- Other
- Nuclear Medicin
- By Application:
- Diagnostic
- Therapeutic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nuclear Medicine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Nuclear medicine is a diagnostic imaging modality that uses radioactive materials to create images of the body. These images can help doctors diagnose and treat medical conditions. Nuclear medicine techniques include:
Some of the major companies in the nuclear medicine market are GE Healthcare, Bracco Imaging, Mallinckrodt, Lantheus Medical Imaging, Bayer, Triad Isotopes, Nordion, Jubilant Pharma, Eli Lilly, SIEMENS, China Isotope & Radiation, Dongcheng, Nuclear Medicin.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Nuclear Medicine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Nuclear Medicine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Nuclear Medicine Market - Supply Chain
4.5. Global Nuclear Medicine Market Forecast
4.5.1. Nuclear Medicine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Nuclear Medicine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Nuclear Medicine Market Absolute $ Opportunity
5. Global Nuclear Medicine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Nuclear Medicine Market Size and Volume Forecast by Type
5.3.1. Tc-99
5.3.2. I-123/131
5.3.3. In-111
5.3.4. Xe-133
5.3.5. Th-201
5.3.6. Ga-67
5.3.7. Other
5.3.8. Nuclear Medicin
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Nuclear Medicine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Nuclear Medicine Market Size and Volume Forecast by Application
6.3.1. Diagnostic
6.3.2. Therapeutic
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Nuclear Medicine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Nuclear Medicine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Nuclear Medicine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Nuclear Medicine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Nuclear Medicine Demand Share Forecast, 2019-2026
9. North America Nuclear Medicine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Nuclear Medicine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Nuclear Medicine Market Size and Volume Forecast by Application
9.4.1. Diagnostic
9.4.2. Therapeutic
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Nuclear Medicine Market Size and Volume Forecast by Type
9.7.1. Tc-99
9.7.2. I-123/131
9.7.3. In-111
9.7.4. Xe-133
9.7.5. Th-201
9.7.6. Ga-67
9.7.7. Other
9.7.8. Nuclear Medicin
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Nuclear Medicine Demand Share Forecast, 2019-2026
10. Latin America Nuclear Medicine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Nuclear Medicine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Nuclear Medicine Market Size and Volume Forecast by Application
10.4.1. Diagnostic
10.4.2. Therapeutic
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Nuclear Medicine Market Size and Volume Forecast by Type
10.7.1. Tc-99
10.7.2. I-123/131
10.7.3. In-111
10.7.4. Xe-133
10.7.5. Th-201
10.7.6. Ga-67
10.7.7. Other
10.7.8. Nuclear Medicin
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Nuclear Medicine Demand Share Forecast, 2019-2026
11. Europe Nuclear Medicine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Nuclear Medicine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Nuclear Medicine Market Size and Volume Forecast by Application
11.4.1. Diagnostic
11.4.2. Therapeutic
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Nuclear Medicine Market Size and Volume Forecast by Type
11.7.1. Tc-99
11.7.2. I-123/131
11.7.3. In-111
11.7.4. Xe-133
11.7.5. Th-201
11.7.6. Ga-67
11.7.7. Other
11.7.8. Nuclear Medicin
11.8. Basis Point Share (BPS) Analysis by Type
11.9. -o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Nuclear Medicine Demand Share, 2019-2026
12. Asia Pacific Nuclear Medicine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Nuclear Medicine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Nuclear Medicine Market Size and Volume Forecast by Application
12.4.1. Diagnostic
12.4.2. Therapeutic
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Nuclear Medicine Market Size and Volume Forecast by Type
12.7.1. Tc-99
12.7.2. I-123/131
12.7.3. In-111
12.7.4. Xe-133
12.7.5. Th-201
12.7.6. Ga-67
12.7.7. Other
12.7.8. Nuclear Medicin
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Nuclear Medicine Demand Share, 2019-2026
13. Middle East & Africa Nuclear Medicine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Nuclear Medicine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Nuclear Medicine Market Size and Volume Forecast by Application
13.4.1. Diagnostic
13.4.2. Therapeutic
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Nuclear Medicine Market Size and Volume Forecast by Type
13.7.1. Tc-99
13.7.2. I-123/131
13.7.3. In-111
13.7.4. Xe-133
13.7.5. Th-201
13.7.6. Ga-67
13.7.7. Other
13.7.8. Nuclear Medicin
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Nuclear Medicine Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Nuclear Medicine Market: Market Share Analysis
14.2. Nuclear Medicine Distributors and Customers
14.3. Nuclear Medicine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GE Healthcare
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bracco Imaging
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Mallinckrodt
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Lantheus Medical Imaging
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bayer
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Triad Isotopes
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Nordion
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Jubilant Pharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Eli Lilly
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. SIEMENS
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. China Isotope & Radiation
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Dongcheng
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Nuclear Medicin
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
